Develops small molecule drugs for the treatment of certain hematopoietic disorders and for the treatment of cancer, pt-100, the company's lead product candidate, has the potential to treat a number of different hematopoietic disorders, such as neutropenia (an abnormally low level of a type of white blood cell called neutrophil) and anemia (an abnormally low level of red blood cells).
